Skip to main content
SpringerLink
Log in

Comparative preclinical antidepressant activity of isolated constituents

  • Chapter
St. John’s Wort and its Active Principles in Depression and Anxiety

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 988 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Butterweck V (2003) Mechanism of action of St John’s Wort in depression. CNS Drugs 17: 539–562

    PubMed  Google Scholar 

  2. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 31(Suppl): 16–21

    PubMed  Google Scholar 

  3. Kaehler ST, Sinner C, Chatterjee SS, Philippu A (1999) Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci Lett 262: 199–202

    Article  PubMed  Google Scholar 

  4. Müller WE, Singer A, Wonnemann M (2001) Hyperforin — Antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34(Suppl 1): 98–102

    Article  Google Scholar 

  5. Singer A, Wonnemann M, Müller WE (1999) Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 290: 1363–1368

    PubMed  Google Scholar 

  6. Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H (1999) Flavonoids from Hypericum perforatum show antidepressant activity in the Forced Swimming Test. Planta Med 66: 3–6

    Article  Google Scholar 

  7. Nöldner M (2001) Antidepressive effekte von johanniskraut und wichtigen inhaltsstoffen im tiermodell. In: WE Müller, M Gastpar (eds): Behandlung von depressiven Patienten in der täglichen Praxis; Stellenwert von Johanniskrautextrakt. LinguaMed Verlags GmbH, 31–42

    Google Scholar 

  8. Nöldner M, Schötz K (2002) Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the Forced Swimming Test. Planta Med 68: 577–580

    Article  PubMed  Google Scholar 

  9. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A (1998) Solubilized hypericin and pseudohy-pericin from Hypericum perforatum exert antidepressant activity in the Forced Swimming Test. Planta Med 64: 291–294

    PubMed  Google Scholar 

  10. Butterweck V, Winterhoff H, Herkenham M (2001) St John’s Wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following shortterm and long-term administration in normal and stressed rats. Mol Psychiatry 6: 547–564

    Article  PubMed  Google Scholar 

  11. Gurevich AI, Dobrynin VN, Kolosov MN, Popravko SA, Ryabova ID, Chernov BK, Derbentseva NA, Aizenman BE, Gargulya AD (1971) Hyperforin an antibiotic from Hypericum perforatum. Antibiotiki 16: 510–513

    PubMed  Google Scholar 

  12. Hübner AT (2003) Treatment with Hypericum perforatum L. does not trigger decreased resistance in Staphylococcus aureus against antibiotics and hyperforin. Phytomedicine 10: 206–208

    Article  PubMed  Google Scholar 

  13. Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC (1999) Antibacterial activity of hyperforin from St. John’s Wort against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet 353: 2129

    Article  Google Scholar 

  14. Chatterjee SS, Nöldner M, Koch E, Erdelmeier C (1998) Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31(Suppl): 7–15

    PubMed  Google Scholar 

  15. Eckert GP, Müller WE (2001) Effects of hyperforin on the fluidity of brain membranes. Pharmacopsychiatry 34(Suppl 1): 22–25

    Article  Google Scholar 

  16. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998) Hyperforin as a possible antidepressant component of Hypericum Extracts. Life Sci 63: 499–510

    Article  PubMed  Google Scholar 

  17. Uebelhack R, Franke L (2001) In vitro effects of St. John’s Wort extract and hyperforin on 5HT uptake and efflux in human blood platelets. Pharmacopsychiatry 34(Suppl 1): 146–147

    Google Scholar 

  18. Fisyunov AI, Lozovaya NA, Tsyntsadze TSh, Yatsenko NM, Chatterjee SS, Krishtal OA (2001) Modulating action of hyperforin on the P-type calcium channels in the membranes of rat cerebellar Purkinje neurons. Neurophysiology 33: 8–14

    Google Scholar 

  19. Krishtal O, Lozovaya N, Fisunov A, Tsintsadze T, Pankratov Y, Kopanitsa M, Chatterjee SS (2001) Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 34(Suppl 1): 74–82

    Article  Google Scholar 

  20. Fisunov A, Lozovaya N, Tsintsadze T, Chatterjee S, Nöldner M, Krishtal O (2000) Hyperforin modulates gating of P-type Ca2+ current in cerebellar Purkinje neurons. Pflügers Arch — Eur J Physiol 440: 427–434

    Article  Google Scholar 

  21. Chatterjee S, Filippov V, Lishko P, Maximyuk O, Nöldner M, Krishtal O (1999) Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci 65: 2395–2405

    PubMed  Google Scholar 

  22. Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K (1999) Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest Virus system. J Recept Signal Transduct Res 19: 59–74

    PubMed  Google Scholar 

  23. Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J, Popadak B, Ernsberger P, Roth BL (2002) In vitro receptor screening of pure constituents of St. John’s Wort reveals novel interactions with a number of GPCRs. Psychopharmacology 162: 193–202

    Article  PubMed  Google Scholar 

  24. Saxena PR, Lawang A (1985) A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn 277: 235–252

    PubMed  Google Scholar 

  25. Greenshaw AJ (1993) Behavioral pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potentials. TIPS 14: 265–270

    PubMed  Google Scholar 

  26. Porsolt RD, Anton G, Blavet N, Jaffre M (1978) Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379–391

    PubMed  Google Scholar 

  27. Porsolt RD (1981) Behavioural despair. In: SJ Enna, JB Malick, E Richelson (eds): Antidepressants: neurochemical, behavioural and clinical perspectives. Raven Press, New York, 121–139

    Google Scholar 

  28. Klusa V, Germane S, Nöldner M, Chatterjee SS (2001) Hypericum extract and hyperforin: Memory-enhancing properties in rodents. Pharmacopsychiatry 34(Suppl 1): 61–69

    Google Scholar 

  29. Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S (2002) Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 164: 423–428

    Article  PubMed  Google Scholar 

  30. Bhattacharya SK, Chakrabarti A, Chatterjee SS (1998) Activity profiles of two hyperforin-containing Hypericum extracts in behavioral models. Pharmacopsychiatry 31(Suppl): 22–29

    PubMed  Google Scholar 

  31. Maier SF, Seligman MEP (1976) Learned helplessness: theory and evidence. J Exp Psychol 1: 3–46

    Google Scholar 

  32. Zanoli P, Rivasi M, Baraldi C, Baraldi M (2002) Pharmacological activity of hyperforin acetate in rats. Behav Pharmacol 13: 645–651

    PubMed  Google Scholar 

  33. Franklin M, Chi JD, Mannel M, Cowen PJ (2000) Acute effects of LI 160 (extract of Hypericum perforatum, St. John’s Wort) and two of its constituents on neuroendocrine responses in the rat. J Psychopharmacol 14: 360–363

    PubMed  Google Scholar 

  34. Franklin M, Cowen PJ (2001) Researching the antidepressant actions of Hypericum perforatum (St. John’s Wort) in animals and man. Pharmacopsychiatry 34(Suppl 1): 29–37

    Google Scholar 

  35. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H (2003) Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73: 627–639

    PubMed  Google Scholar 

  36. Biber A, Fischer H, Römer A, Chatterjee SS (1998) Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31(Suppl): 36–43

    Google Scholar 

  37. Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S (2003) Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 75: 25–30

    PubMed  Google Scholar 

  38. Keller JH, Karas M, Müller WE, Volmer DA, Eckert GP, Tawab MA, Blume HH, Dingermann T, Schubert-Zsilavecz M (2003) Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 75: 6084–6088

    PubMed  Google Scholar 

  39. Nahrstedt A, Butterweck V (1997) Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30(Suppl): 129–134

    PubMed  Google Scholar 

  40. Morales MA, Lozoya X (1994) Calcium-antagonist effects of quercetin on aortic smooth muscle. Planta Med 60: 313–317

    PubMed  Google Scholar 

  41. Abdalla S, Zarga MA, Afifi F, Al-Khalil S, Mahasneh A, Sabri S (1989) Effects of 3,3′-di-Omethylquercetin on guinea-pig isolated smooth muscle. J Pharm Pharmacol 41: 138–141

    PubMed  Google Scholar 

  42. Trute A, Gross J, Mutschler E, Nahrstedt A (1997) In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Med 63: 125–129

    PubMed  Google Scholar 

  43. Sparenberg B, Demisch L, Hölzl J (1993) Untersuchungen über antidepressive Wirkstoffe von Johanniskraut. Pharm Ztg Wiss Nr. 2 6./138: 50–54

    Google Scholar 

  44. Baureithel KH, Berger Büter K, Engesser A, Burkard W, Schaffner W (1997) Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 72: 153–157

    PubMed  Google Scholar 

  45. Tekel’ová D, Repcák M, Zemková E, Tóth J (2000) Quantitative changes of dianthrones, hyper-forin and flavonoids content in the flower ontogenesis of Hypericum perforatum. Planta Med 66: 778–780

    PubMed  Google Scholar 

  46. Umek A, Kreft S, Kartnig T, Heydel B (1999) Quantitative phytochemical analyses of six Hypericum species growing in Slovenia. Planta Med 65: 388–390

    Google Scholar 

  47. Mártonfi P, Repcák M, Ciccarelli D, Garbari F (2001) Hypericum perforatum L. — Chemotype without rutin from Italy. Biochem Syst Ecol 29: 659–661

    PubMed  Google Scholar 

  48. Greeson JM, Sanford B, Monti DA (2001) St. John’s Wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 153: 402–414

    PubMed  Google Scholar 

  49. Bork PM, Bacher S, Schmitz ML, Kaspers U, Heinrich M (1999) Hypericin as a non-antioxidant inhibitor of NF-κB. Planta Med 65: 297–300

    PubMed  Google Scholar 

  50. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H (1984) Inhibition of monoamine oxidase by hypericin. Planta Med 50: 272–274

    PubMed  Google Scholar 

  51. Bladt S, Wagner H (1993) MAO-Hemmung durch Fraktionen und Inhaltsstoffe von Hypericum-Extrakt. Nervenheilkunde 12: 349–352

    Google Scholar 

  52. Raffa RB (1998) Screen of receptor and uptake-site activity of hypericin component of St. John’s Wort reveals σ receptor binding. Life Sci 62: 265–270

    Google Scholar 

  53. Simmen U, Higelin J, Berger-Büter K, Schaffner W, Lundstrom K (2001) Neurochemical studies with St. John’s Wort in vitro. Pharmacopsychiatry 34(Suppl 1): 137–142

    PubMed  Google Scholar 

  54. Simmen U, Bobirnac I, Ullmer C, Lübbert H, Berger-Büter K, Schaffner W, Schoeffter Philippe (2003) Antagonist effect of pseudohypericin at CRF1 receptors. Eur J Pharmacol 458: 251–256

    PubMed  Google Scholar 

  55. Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A (2003) Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: A pharmacokinetic study in rats. Planta Med 69: 189–192

    Article  PubMed  Google Scholar 

  56. Butterweck V, Korte B, Winterhoff H (2001) Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 34(Suppl 1): 2–7

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Willmar Schwabe GmbH & Co KG, Willmar-Schwabe-Straße 4, 76227, Karlsruhe, Germany

    Michael Nöldner

Authors
  1. Michael Nöldner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut für Naturwissenschaftler, Biozentrum Universität Frankfurt, Marie-Curie-Str.9, 60439, Frankfurt, Germany

    Walter E. Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Nöldner, M. (2005). Comparative preclinical antidepressant activity of isolated constituents. In: Müller, W.E. (eds) St. John’s Wort and its Active Principles in Depression and Anxiety. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7338-5_7

Download citation

Publish with us

Policies and ethics

Search

Navigation